Skip to main content
PMC home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1997 Dec;81(12):1073–1079. doi: 10.1136/bjo.81.12.1073

Surgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor β2

M Minihan 1, M Goggin 1, P Cleary 1
PMCID: PMC1722094  PMID: 9497468

Abstract

BACKGROUND—Vitrectomy and gas tamponade has become a recognised technique for the treatment of macular holes. In an attempt to improve the anatomic and visual success of the procedure, various adjunctive therapies—cytokines, serum, and platelets—have been employed. A consecutive series of 85 eyes which underwent macular hole surgery using gas tamponade alone, or gas tamponade with either the cytokine transforming growth factor β2 (TGF-β2) or autologous platelet concentrate is reported.
METHODS—Twenty eyes had vitrectomy and 20% SF6 gas tamponade; 15 had vitrectomy, 20% SF6 gas, and TGF-β2; 50 had vitrectomy, 16% C3F8 gas tamponade, and 0.1 ml of autologous platelet concentrate prepared during the procedure.
RESULTS—Anatomic success occurred in 86% of eyes, with 96% of the platelet treated group achieving closure of the macular hole. Visual acuity improved by two lines or more in 65% of the SF6 only group, 33% of those treated with TGF-β2, and in 74% of the platelet treated group. In the platelet treated group 40% achieved 6/12 or better and 62% achieved 6/18 or better. The best visual results were obtained in stage 2 holes.
CONCLUSION—Vitrectomy for macular holes is often of benefit and patients may recover good visual acuity, especially early in the disease process. The procedure has a number of serious complications, and the postoperative posturing requirement is difficult. Patients need to be informed of such concerns before surgery.



Full Text

The Full Text of this article is available as a PDF (134.2 KB).

Figure 1  .

Figure 1  

Open in a new tab

Pre and postoperative logMAR visual acuity of stage 2 holes.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bacon A. S., Davison C. R., Patel B. C., Frazer D. G., Ficker L. A., Dart J. K. Infective endophthalmitis following vitreoretinal surgery. Eye (Lond) 1993;7(Pt 4):529–534. doi: 10.1038/eye.1993.115. [DOI] [PubMed] [Google Scholar]
  2. Barrie T. Macular holes. Br J Ophthalmol. 1995 Jun;79(6):511–512. doi: 10.1136/bjo.79.6.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Christmas N. J., Skolik S. A., Howard M. A., Saito Y., Barnstable C. J., Liggett P. E. Treatment of retinal breaks with autologous serum in an experimental model. Ophthalmology. 1995 Feb;102(2):263–271. doi: 10.1016/s0161-6420(95)31046-9. [DOI] [PubMed] [Google Scholar]
  4. Ezra E., Arden G. B., Riordan-Eva P., Aylward G. W., Gregor Z. J. Visual field loss following vitrectomy for stage 2 and 3 macular holes. Br J Ophthalmol. 1996 Jun;80(6):519–525. doi: 10.1136/bjo.80.6.519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fine S. L. Vitreous surgery for macular hole in perspective. Is there an indication? Arch Ophthalmol. 1991 May;109(5):635–636. doi: 10.1001/archopht.1991.01080050049026. [DOI] [PubMed] [Google Scholar]
  6. Gass J. D. Idiopathic senile macular hole. Its early stages and pathogenesis. Arch Ophthalmol. 1988 May;106(5):629–639. doi: 10.1001/archopht.1988.01060130683026. [DOI] [PubMed] [Google Scholar]
  7. Gass J. D. Reappraisal of biomicroscopic classification of stages of development of a macular hole. Am J Ophthalmol. 1995 Jun;119(6):752–759. doi: 10.1016/s0002-9394(14)72781-3. [DOI] [PubMed] [Google Scholar]
  8. Gaudric A., Massin P., Paques M., Santiago P. Y., Guez J. E., Le Gargasson J. F., Mundler O., Drouet L. Autologous platelet concentrate for the treatment of full-thickness macular holes. Graefes Arch Clin Exp Ophthalmol. 1995 Sep;233(9):549–554. doi: 10.1007/BF00404704. [DOI] [PubMed] [Google Scholar]
  9. Glaser B. M., Michels R. G., Kuppermann B. D., Sjaarda R. N., Pena R. A. Transforming growth factor-beta 2 for the treatment of full-thickness macular holes. A prospective randomized study. Ophthalmology. 1992 Jul;99(7):1162–1173. doi: 10.1016/s0161-6420(92)31837-8. [DOI] [PubMed] [Google Scholar]
  10. Ie D., Glaser B. M., Thompson J. T., Sjaarda R. N., Gordon L. W. Retreatment of full-thickness macular holes persisting after prior vitrectomy. A pilot study. Ophthalmology. 1993 Dec;100(12):1787–1793. doi: 10.1016/s0161-6420(93)31397-7. [DOI] [PubMed] [Google Scholar]
  11. Kelly N. E., Wendel R. T. Vitreous surgery for idiopathic macular holes. Results of a pilot study. Arch Ophthalmol. 1991 May;109(5):654–659. doi: 10.1001/archopht.1991.01080050068031. [DOI] [PubMed] [Google Scholar]
  12. Korobelnik J. F., Hannouche D., Belayachi N., Branger M., Guez J. E., Hoang-Xuan T. Autologous platelet concentrate as an adjunct in macular hole healing: a pilot study. Ophthalmology. 1996 Apr;103(4):590–594. doi: 10.1016/s0161-6420(96)30648-9. [DOI] [PubMed] [Google Scholar]
  13. Lansing M. B., Glaser B. M., Liss H., Hanham A., Thompson J. T., Sjaarda R. N., Gordon A. J. The effect of pars plana vitrectomy and transforming growth factor-beta 2 without epiretinal membrane peeling on full-thickness macular holes. Ophthalmology. 1993 Jun;100(6):868–872. doi: 10.1016/s0161-6420(93)31561-7. [DOI] [PubMed] [Google Scholar]
  14. Lewis H., Cowan G. M., Straatsma B. R. Apparent disappearance of a macular hole associated with development of an epiretinal membrane. Am J Ophthalmol. 1986 Aug 15;102(2):172–175. doi: 10.1016/0002-9394(86)90139-x. [DOI] [PubMed] [Google Scholar]
  15. Liggett P. E., Skolik D. S., Horio B., Saito Y., Alfaro V., Mieler W. Human autologous serum for the treatment of full-thickness macular holes. A preliminary study. Ophthalmology. 1995 Jul;102(7):1071–1076. doi: 10.1016/s0161-6420(95)30909-8. [DOI] [PubMed] [Google Scholar]
  16. Melberg N. S., Thomas M. A. Visual field loss after pars plana vitrectomy with air/fluid exchange. Am J Ophthalmol. 1995 Sep;120(3):386–388. doi: 10.1016/s0002-9394(14)72169-5. [DOI] [PubMed] [Google Scholar]
  17. Park S. S., Marcus D. M., Duker J. S., Pesavento R. D., Topping T. M., Frederick A. R., Jr, D'Amico D. J. Posterior segment complications after vitrectomy for macular hole. Ophthalmology. 1995 May;102(5):775–781. doi: 10.1016/s0161-6420(95)30956-6. [DOI] [PubMed] [Google Scholar]
  18. Pendergast S. D., McCuen B. W., 2nd Visual field loss after macular hole surgery. Ophthalmology. 1996 Jul;103(7):1069–1077. doi: 10.1016/s0161-6420(96)30565-4. [DOI] [PubMed] [Google Scholar]
  19. Perkins T. W., Cardakli U. F., Eisele J. R., Kaufman P. L., Heatley G. A. Adjunctive mitomycin C in Molteno implant surgery. Ophthalmology. 1995 Jan;102(1):91–97. doi: 10.1016/s0161-6420(95)31048-2. [DOI] [PubMed] [Google Scholar]
  20. Polk T. D., Smiddy W. E., Flynn H. W., Jr Bilateral visual function after macular hole surgery. Ophthalmology. 1996 Mar;103(3):422–426. doi: 10.1016/s0161-6420(96)30676-3. [DOI] [PubMed] [Google Scholar]
  21. Ruby A. J., Williams D. F., Grand M. G., Thomas M. A., Meredith T. A., Boniuk I., Olk R. J. Pars plana vitrectomy for treatment of stage 2 macular holes. Arch Ophthalmol. 1994 Mar;112(3):359–364. doi: 10.1001/archopht.1994.01090150089029. [DOI] [PubMed] [Google Scholar]
  22. Ryan E. H., Jr, Gilbert H. D. Results of surgical treatment of recent-onset full-thickness idiopathic macular holes. Arch Ophthalmol. 1994 Dec;112(12):1545–1553. doi: 10.1001/archopht.1994.01090240051025. [DOI] [PubMed] [Google Scholar]
  23. Schocket S. S., Lakhanpal V., Miao X. P., Kelman S., Billings E. Laser treatment of macular holes. Ophthalmology. 1988 May;95(5):574–582. doi: 10.1016/s0161-6420(88)33137-4. [DOI] [PubMed] [Google Scholar]
  24. Smiddy W. E., Glaser B. M., Green W. R., Connor T. B., Jr, Roberts A. B., Lucas R., Sporn M. B. Transforming growth factor beta. A biologic chorioretinal glue. Arch Ophthalmol. 1989 Apr;107(4):577–580. doi: 10.1001/archopht.1989.01070010591036. [DOI] [PubMed] [Google Scholar]
  25. Smiddy W. E., Glaser B. M., Thompson J. T., Sjaarda R. N., Flynn H. W., Jr, Hanham A., Murphy R. P. Transforming growth factor-beta 2 significantly enhances the ability to flatten the rim of subretinal fluid surrounding macular holes. Preliminary anatomic results of a multicenter prospective randomized study. Retina. 1993;13(4):296–301. [PubMed] [Google Scholar]
  26. Smiddy W. E., Sjaarda R. N., Glaser B. M., Flynn H. W., Jr, Thompson J. T., Hanham A., Murphy R. P. Reoperation after failed macular hole surgery. Retina. 1996;16(1):13–18. doi: 10.1097/00006982-199616010-00004. [DOI] [PubMed] [Google Scholar]
  27. Steed D. L., Goslen J. B., Holloway G. A., Malone J. M., Bunt T. J., Webster M. W. Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo. Diabetes Care. 1992 Nov;15(11):1598–1604. doi: 10.2337/diacare.15.11.1598. [DOI] [PubMed] [Google Scholar]
  28. Thompson J. T., Glaser B. M., Sjaarda R. N., Murphy R. P., Hanham A. Effects of intraocular bubble duration in the treatment of macular holes by vitrectomy and transforming growth factor-beta 2. Ophthalmology. 1994 Jul;101(7):1195–1200. doi: 10.1016/s0161-6420(94)31187-0. [DOI] [PubMed] [Google Scholar]
  29. Thompson J. T., Glaser B. M., Sjaarda R. N., Murphy R. P. Progression of nuclear sclerosis and long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes. Am J Ophthalmol. 1995 Jan;119(1):48–54. doi: 10.1016/s0002-9394(14)73812-7. [DOI] [PubMed] [Google Scholar]
  30. Wendel R. T., Patel A. C., Kelly N. E., Salzano T. C., Wells J. W., Novack G. D. Vitreous surgery for macular holes. Ophthalmology. 1993 Nov;100(11):1671–1676. doi: 10.1016/s0161-6420(93)31419-3. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES